이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 고형 종양(VISTA-101)에서 KVA12123 단독 및 Pembrolizumab 병용 요법의 임상 시험

2026년 9월 30일 업데이트: Kineta Inc.

A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors. The study included dose escalation and planned dose expansion phases. Only the dose escalation phases were conducted. The planned dose expansion phase were not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern.

The study sought to assess the safety of KVA12123 [TBS-2025] given alone or with pembrolizumab and to identify appropriate doses for future clinical trials. Participants in the doses for future clinical trials. Participants in the dose escalation phases visited study sites for treatment and safety assessments. These assessments included blood samples, imaging scans, physical examinations, and heart function tests.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

This was a first-in-human (FIH), Phase 1/2, open-label, multicenter, dose escalation, and dose expansion study designed to evaluate the safety, tolerability, PK, immunogenicity, and tumor response of the investigational drug KVA12123, subsequently designated TBS-2025, alone and in combination with pembrolizumab in adults with relapsed or refractory advanced solid tumors. The study was planned to conduct in 4 planned parts: Parts A and B focus on dose escalation (single-agent and in combination), and Parts C and D focus on dose expansion (single-agent and in combination).

Parts A (single-agent KVA12123) and B (KVA12123 + pembrolizumab) allowed up to 10 dose escalation cohorts: 6 in Part A and 4 in Part B, with 1 to 6 participants per cohorts. These parts were intended to characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary tumor response, and to inform the selection of recommended phase 2 doses.

Parts C (single-agent KVA12123) and D (KVA12123 + pembrolizumab) were planned but not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern.

연구 유형

중재적

등록 (실제)

40

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Santa Monica, California, 미국, 90404
        • UCLA Health (Santa Monica Cancer Care)
    • Colorado
      • Denver, Colorado, 미국, 80218
        • Sarah Cannon Research Institute at HealthONE
    • Florida
      • Sarasota, Florida, 미국, 34232
        • Sarah Cannon Research Institute at Florida Cancer Specialists
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • University of Michigan
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19107
        • Thomas Jefferson University
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • Sarah Cannon Research Institute at Tennessee Oncology
    • Washington
      • Seattle, Washington, 미국, 98109
        • Fred Hutchinson Cancer Research Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

  1. Willing and able to provide informed consent.

  2. Be at least 18 years of age at the time of consent.

  3. Has histologically or cytologically confirmed, locally advanced or metastatic solid tumor that has progressed or was non-responsive to standard of care therapy and for which no available curative therapy exists.

  4. Has expected survival ≥16 weeks.

  5. Presence of measurable disease by iRECIST.

  6. Has an ECOG performance status score of 0 or 1.

  7. Has adequate organ function within 10 days prior to the start of study treatment.

  8. Has normal thyroid function or hypothyroid with stable supplementation.

  9. Has consented to the collection of archival tissue prior to study treatment initiation.

  10. Participants with prior exposure to systemic anticancer therapy including investigational agents following a 4-week washout period are eligible. Participants with prior small molecule targeted therapy or other short half-life drugs are eligible following a 2-week washout period.

  11. Participants having prior curative radiation therapy completed 2 weeks prior to study drug administration or prior palliative radiation therapy to non-CNS disease completed at least 1 week prior to study drug administration are eligible.

  12. HIV-infected participants must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease.

  13. Participants with a history of HBV infection having durable HBsAg loss and undetectable serum HBV DNA no longer requiring treatment are eligible.

  14. Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening and participants have completed curative antiviral therapy.

  15. Post-menopausal women and surgically sterile men and women are permitted.

  16. Patients of childbearing potential are permitted to participate under the following conditions:

    1. Must have negative urine pregnancy test result within 72 hrs prior to the first dose of any study drug
    2. Must agree not to become pregnant during the study and for 120 days after the final dose of any study drug
    3. Must agree not to breastfeed or donate ova, starting at time of informed consent and continuing through 120 days after the final dose of any study drug
    4. If sexually active in a way that could lead to pregnancy, must consistently use 2 acceptable methods of birth control (contraception), at least 1 of which must be highly effective starting at time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug.
  17. Patients who can father children are permitted to participate under the following conditions:

    1. Must agree not to donate sperm starting at the time of informed consent and continuing throughout the study period and for 120 days after the final dose of any study drug
    2. If sexually active with a person of childbearing potential in a way that could lead to pregnancy, must consistently use 2 acceptable methods of birth control (contraception), at least 1 of which must be highly effective starting at the time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug
    3. If sexually active with a person who is pregnant or breastfeeding, must consistently use a condom starting at time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug.
  18. Must be willing and able to comply with the trial procedures and the follow-up schedule.

Exclusion Criteria

  1. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression.
  2. Concurrent cancer other than disease under study requiring systemic treatment. Participants with basal cell or squamous cell skin cancer treated with curative intent, carcinoma in-situ of the cervix or breast treated with curative intent, RAI stage 0 Chronic Lymphocytic Leukemia, monoclonal gammopathy of undetermined significance, superficial bladder cancer or very low and low risk prostate cancer (localized Gleason score ≤ 6) under active surveillance are eligible.
  3. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
  4. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg QD of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.
  5. History of (non-infectious) pneumonitis/interstitial lung disease (ILD) that required steroids or current pneumonitis/ILD.
  6. Prior treatment with VISTA-targeted therapy.
  7. Prior history of allogeneic, solid organ or stem cell transplant, or adoptive T-cell transplant.
  8. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, LAG-3, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE).
  9. Active known or suspected autoimmune disease that has required systemic treatment within the past year. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  10. Prior systemic anticancer therapy, including investigational agents, within 4 weeks of treatment. Participants with prior small molecule targeted therapy or other short half-life drugs are eligible following a 2-week washout period.
  11. Has received prior radiation therapy within 2 weeks of start of study treatment or has a history of radiation pneumonitis.
  12. Has received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of study treatment.
  13. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.
  14. Any requirement for daily supplemental oxygen.
  15. Any condition requiring systemic treatment with corticosteroids (>10 mg QD prednisone equivalents) or other immunosuppressive medications within 14 days before the first dose of study drug.
  16. Serious or poorly controlled cardiovascular disease.
  17. Chronic hepatitis B or C.
  18. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
  19. Has an active infection requiring systemic therapy.
  20. Known active or latent tuberculosis.
  21. If the participant had major surgery, must have recovered adequately from the procedure and/or any complications.
  22. Toxicities arising from prior cancer therapy that have not resolved to Grade 1 or baseline.
  23. Red blood cell or platelet infusion within the preceding 2 weeks.
  24. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  25. Known hypersensitivity to any excipient contained in the drug formulation of KVA12123.
  26. Any significant history of drug allergy as assessed by the investigator.
  27. Positive urine pregnancy test within 72 hrs of study drug administration.
  28. Participants who are breastfeeding, pregnant, or planning to become pregnant from time of informed consent until at least 120 days after final dose of study drug.
  29. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study.
  30. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  31. Inability to comply with study procedures.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: KVA12123 [TBS-2025] Monotherapy Dose Escalation

Part A will consist of dose escalation with KVA12123 [TBS-2025] administered as a single agent in participants with advanced solid tumors.

Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.

실험적: KVA12123 [TBS-2025] Plus Pembrolizumab Dose Escalation

Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.

Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.

다른 이름들:
  • 키트루다
실험적: KVA12123 [TBS-2025] Monotherapy Dose Expansion

Part C will consist of dose expansion with KVA12123 [TBS-2025] administered as a single agent at the RP2D in participants with advanced solid tumors. Part C was not initiated.

KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.

실험적: KVA12123 Plus Pembrolizumab Dose Expansion

Part D will consist of dose expansion with KVA12123 [TBS-2025] administered at the RP2D in combination with a fixed dose of pembrolizumab. Part D was not initiated.

KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.

다른 이름들:
  • 키트루다

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Adverse Events
기간: Through study completion, an average of 1 year

Type and frequency of adverse events as assessed by CTCAE v5.0.

Through study completion, an average of 1 year
AEs related to study drug
기간: Through study completion, an average of 1 year

Type and frequency of treatment related adverse events as assessed by CTCAE v4.0.

Through study completion, an average of 1 year
Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)
기간: Through study completion, an average of 1 year

Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) of KVA12123 when administered alone and in combination with pembrolizumab in participants with advanced solid tumors (milligrams or milligrams/kilogram).

Through study completion, an average of 1 year

2차 결과 측정

결과 측정
측정값 설명
기간
Pharmacokinetic (PK) profile of KVA12123 (Cmax)
기간: Through study completion, an average of 1 year

maximum serum concentration (micrograms/milliliter [mL])

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (Cmin)
기간: Through study completion, an average of 1 year

trough serum concentration (micrograms/mL)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (tmax)
기간: Through study completion, an average of 1 year

time to maximum serum concentration (hours)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (AUC)
기간: Through study completion, an average of 1 year

Area under the concentration-time curve (microgram*mL/hour)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (t1/2)
기간: Through study completion, an average of 1 year

Elimination half life (hours)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (Vd)
기간: Through study completion, an average of 1 year

Volume of distribution (milliliter or liter)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (Cl)
기간: Through study completion, an average of 1 year

Clearance (mL/hour)

Through study completion, an average of 1 year
Concentration of anti-KVA12123 antibodies in serum
기간: Through study completion, an average of 1 year

Change from baseline in anti-KVA12123 antibodies in serum (antibody concentration per mL)

Through study completion, an average of 1 year
Number of participants with progressive disease following treatment with KVA12123
기간: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with progressive disease following treatment with KVA12123 in combination with pembrolizumab
기간: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with stable disease following treatment with KVA12123
기간: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with stable disease following treatment with KVA12123 plus pembrolizumab
기간: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with partial response following treatment with KVA12123
기간: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with partial response following treatment with KVA12123 plus pembrolizumab
기간: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with complete response following treatment with KVA12123
기간: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with complete response following treatment with KVA12123 plus pembrolizumab
기간: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: Thierry Guillaudeux, PhD, Kineta Inc.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 3월 3일

기본 완료 (실제)

2025년 10월 16일

연구 완료 (실제)

2025년 12월 18일

연구 등록 날짜

최초 제출

2022년 12월 9일

QC 기준을 충족하는 최초 제출

2023년 1월 24일

처음 게시됨 (실제)

2023년 2월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • VISTA-101
  • KEYNOTE-E67 (기타 식별자: Merck, Sharp & Dohme, LLC)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .